Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for driver gene-negative advanced NSCLC: a single-center retrospective real-world study
This study confirms the promising efficacy and acceptable safety profile of AK104 combination therapy in patients with driver gene-negative advanced NSCLC. These findings collectively support the need for further large-scale prospective studies to validate its clinical utility.
Authors
- Kaihua Lu
- Lulin Zeng
- Yan Xiang
- Ao Sun
Institutions
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-16
- DOI
- https://doi.org/10.3389/fonc.2026.1718151
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Nanjing Medical University